Show simple item record

dc.contributor.authorSchulz, Christian
dc.contributor.authorSchütte, Kerstin
dc.contributor.authorKropf, Siegfried
dc.contributor.authorSchmitt, Friedhelm C
dc.contributor.authorVasapolli, Riccardo
dc.contributor.authorKliegis, Leon M
dc.contributor.authorRiegger, Antonia
dc.contributor.authorMalfertheiner, Peter
dc.date.accessioned2016-03-18T10:48:42Zen
dc.date.available2016-03-18T10:48:42Zen
dc.date.issued2016en
dc.identifier.citationRiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. 2016, 17 (1):111 Trialsen
dc.identifier.issn1745-6215en
dc.identifier.pmid26926775en
dc.identifier.doi10.1186/s13063-016-1205-8en
dc.identifier.urihttp://hdl.handle.net/10033/602193en
dc.description.abstractHepatic encephalopathy (HE) is a clinically significant complication of liver cirrhosis impacting on the patients' quality of life. Minimal hepatic encephalopathy (MHE) is diagnosed by psychometric tests, found in up to 80 % of patients with liver cirrhosis and carries a high risk of progression to overt HE. Continuous therapy with rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence of HE and HE-related hospitalizations in randomized, double-blind, placebo-controlled clinical trials. Rifaximin is approved for the therapy of overt HE in Germany. Treatment with lactulose has been shown to improve cognitive functions in patients with liver cirrhosis. Data from prospective clinical trials comparing the efficacy of rifaximin alone against a combination of rifaximin and lactulose in the treatment of MHE are scarce. Changes in the microbiome of the upper and lower gastrointestinal tract as a result of therapy with rifaximin have not yet been addressed in clinical studies.
dc.language.isoenen
dc.titleRiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalTrialsen
refterms.dateFOA2018-06-13T19:41:30Z
html.description.abstractHepatic encephalopathy (HE) is a clinically significant complication of liver cirrhosis impacting on the patients' quality of life. Minimal hepatic encephalopathy (MHE) is diagnosed by psychometric tests, found in up to 80 % of patients with liver cirrhosis and carries a high risk of progression to overt HE. Continuous therapy with rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence of HE and HE-related hospitalizations in randomized, double-blind, placebo-controlled clinical trials. Rifaximin is approved for the therapy of overt HE in Germany. Treatment with lactulose has been shown to improve cognitive functions in patients with liver cirrhosis. Data from prospective clinical trials comparing the efficacy of rifaximin alone against a combination of rifaximin and lactulose in the treatment of MHE are scarce. Changes in the microbiome of the upper and lower gastrointestinal tract as a result of therapy with rifaximin have not yet been addressed in clinical studies.


Files in this item

Thumbnail
Name:
Schulz et al.pdf
Size:
563.8Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record